secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2022-12-13T23:59:59+00:00
Accession:  0000950142-22-003344
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

vTv Therapeutics appoints Steven Tuch as CFO, effective Dec 8, 2022
-------------------------------------------------------------------

- Steven Tuch appointed CFO; base salary $450K, target bonus 40% of salary.
- Tuch granted options for 500K shares vesting over 3 years; performance equity tied to $50M financing.
- Severance: 9 months base salary if terminated without cause or resigns for good reason.
- Tuch previously led Rallybio IPO ($92.7M) and 7 years at BMO Capital Markets.
- Company preparing for Phase 3 trials of lead candidate TTP399 for type 1 diabetes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000095014222003344/0000950142-22-003344-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000095014222003344/eh220309936_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950142-22-003344

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer